Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study | Zendy

Xiaojie Wu | Zendy; Nanyang Li | Zendy; Guoqin Wang | Zendy; Wei Liu | Zendy; Jicheng Yu | Zendy; Guoying Cao | Zendy; Jingjing Wang | Zendy; Yuancheng Chen | Zendy; Juan Ma | Zendy; Jufang Wu | Zendy; Haijing Yang | Zendy; Xiaomeng Mao | Zendy; Jinjie He | Zendy; Yiqi Yu | Zendy; Chao Qiu | Zendy; Ning Li | Zendy; Sheng Yao | Zendy; Hui Feng | Zendy; Jinghua Yan | Zendy; Wenhong Zhang | Zendy; Jing Zhang | Zendy

Open Access

Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study

Author(s) -

Xiaojie Wu,

Nanyang Li,

Guoqin Wang,

Wei Liu,

Jicheng Yu,

Guoying Cao,

Jingjing Wang,

Yuancheng Chen,

Juan Ma,

Jufang Wu,

Haijing Yang,

Xiaomeng Mao,

Jinjie He,

Yiqi Yu,

Chao Qiu,

Ning Li,

Sheng Yao,

Hui Feng,

Jinghua Yan,

Wenhong Zhang,

Jing Zhang

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00350-21

Subject(s) - tolerability , placebo , pharmacokinetics , medicine , immunogenicity , adverse effect , pharmacodynamics , pharmacology , anesthesia , immunology , antibody , pathology , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research